Cardiome/Astellas Schedule Kynapid Meeting With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Meanwhile, Astellas yanks its Canadian new drug submission for the atrial fibrillation candidate to align its North American regulatory strategy.
You may also be interested in...
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
Astellas Bows Out Of The CVT Sweepstakes, But What’s Next?
Japanese pharma drops lawsuit, ends its bid to buy cardiovascular-focused U.S. biotech, and hunts for other possibilities.